As of March 31, 2025, Artiva had cash, cash equivalents, and investments of $166.0 million which is expected to fund operations into Q2 2027.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARTV:
- Biotech Alert: Searches spiking for these stocks today
- Artiva CMO Thorsten Graef switches to advisor role, Subhashis Banerjee succeeds
- Promising Outlook for Artiva Biotherapeutics Amid Strategic Manufacturing and Regulatory Support
- Artiva Biotherapeutics Reports 2024 Financial Results
- Artiva Biotherapeutics: Strong Buy Rating Backed by Promising Pipeline and Financial Stability